(-0.07%) 5 304.50 points
(-0.02%) 40 134 points
(-0.11%) 18 484 points
(0.77%) $81.98
(-1.75%) $1.688
(0.28%) $2 218.80
(-0.64%) $24.59
(-0.01%) $909.60
(0.46%) $0.928
(0.69%) $10.84
(0.28%) $0.793
(-0.15%) $92.31
Live Chart Being Loaded With Signals
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis...
Stats | |
---|---|
Today's Volume | 891 670 |
Average Volume | 1.51M |
Market Cap | 158.21M |
EPS | SEK0 ( 2024-02-20 ) |
Next earnings date | ( SEK0 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -3.30 |
ATR14 | SEK0.00300 (1.01%) |
Volume Correlation
InDex Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
InDex Pharmaceuticals Correlation - Currency/Commodity
InDex Pharmaceuticals Financials
Annual | 2023 |
Revenue: | SEK97.51M |
Gross Profit: | SEK-95.71M (-98.16 %) |
EPS: | SEK-0.180 |
Q4 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-304 000 (0.00 %) |
EPS: | SEK-0.200 |
Q3 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-1.56M (0.00 %) |
EPS: | SEK-0.0712 |
Q2 | 2023 |
Revenue: | SEK97.51M |
Gross Profit: | SEK96.42M (98.88 %) |
EPS: | SEK0.170 |
Financial Reports:
No articles found.
InDex Pharmaceuticals
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators